Thermo Fisher Scientific Inc
NYSE:TMO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
501.29
623.8136
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
Current Portion of Long-Term Debt
Thermo Fisher Scientific Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Current Portion of Long-Term Debt
$4.1B
|
CAGR 3-Years
501%
|
CAGR 5-Years
44%
|
CAGR 10-Years
3%
|
|
|
Danaher Corp
NYSE:DHR
|
Current Portion of Long-Term Debt
$1.2B
|
CAGR 3-Years
456%
|
CAGR 5-Years
2%
|
CAGR 10-Years
33%
|
|
|
West Pharmaceutical Services Inc
NYSE:WST
|
Current Portion of Long-Term Debt
$900k
|
CAGR 3-Years
-73%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-29%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Current Portion of Long-Term Debt
$185.8m
|
CAGR 3-Years
51%
|
CAGR 5-Years
31%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Current Portion of Long-Term Debt
$1.2B
|
CAGR 3-Years
137%
|
CAGR 5-Years
66%
|
CAGR 10-Years
50%
|
|
Thermo Fisher Scientific Inc
Glance View
Thermo Fisher Scientific Inc. stands as a towering entity in the life sciences industry, intricately weaving together science, technology, and business to drive scientific progress and innovation. Founded through a merger of Thermo Electron and Fisher Scientific in 2006, the company has grown exponentially to become a formidable partner for researchers, academicians, and clinicians worldwide. Its business model is built around a broad portfolio of offerings, including laboratory instruments, analytical tools, and consumables, which are crucial for research and quality control. By emphasizing research and development, Thermo Fisher has consistently advanced its technologies, ensuring that its solutions remain indispensable to ventures in pharmaceuticals, biotechnology, and diagnostics. The strategic acquisition of complementary businesses has been a key facet of Thermo Fisher’s growth, fortifying its position across various scientific fields. In essence, the company thrives on understanding the increasingly complex demands of the scientific community. It generates revenue by capitalizing on its diverse product lineup, subscription-based services, and personalized solutions that cater to specific client needs—ranging from equipment used to perform intricate genomic sequencing to reagents required for advanced laboratory experiments. Thus, Thermo Fisher sustains its financial health through a combination of one-time sales and recurring revenue streams, a strategy that not only reflects its adaptability but also ensures long-term profitability and market leadership in the ever-evolving landscape of scientific research.
See Also
What is Thermo Fisher Scientific Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
4.1B
USD
Based on the financial report for Sep 28, 2024, Thermo Fisher Scientific Inc's Current Portion of Long-Term Debt amounts to 4.1B USD.
What is Thermo Fisher Scientific Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
3%
Over the last year, the Current Portion of Long-Term Debt growth was -14%. The average annual Current Portion of Long-Term Debt growth rates for Thermo Fisher Scientific Inc have been 501% over the past three years , 44% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet